Inobrodib;口服first-in-class p300 / CBP抑制剂药物
CellCentric是临床阶段的生物科技公司;科学驱动的,病人集中。我们领导在抑制p300 / CBP治疗多个特定的癌症类型。我们的目标是发展我们first-in-class药物,inobrodib,尽快和尽可能有效地,造福患者。
最新微博@CellCentric
我们开创性的重要一步p300 / CBP抑制剂,inobrodib。影响癌症患者。我们感谢@endpts覆盖许多新闻:https://endpts.com/exclusive-pfizer-to-invest-25m-into-uk-biotech-cellcentric-with-epigenetics-approach-to-cancer/
我们的一个重要里程碑口服抗癌药物,inobrodib。从@pfizer 25美元的战略投资。见新闻稿:https://www.cellcentric.com/press-release/cellcentric-announces-25m-strategic-investment-from-pfizer/
我们的首席医疗官评论FDA孤儿药指定消息。有助于加快开发/采用治疗多发性骨髓瘤。参见:https://www.cellcentric.com/press-release/cellcentric-granted-fda-orphan-drug-designation-for-inobrodib-ccs1477-for-the-treatment-of-multiple-myeloma/
我们开创性的重要一步p300 / CBP抑制剂,inobrodib。影响癌症患者。我们感谢@endpts覆盖许多新闻:https://endpts.com/exclusive-pfizer-to-invest-25m-into-uk-biotech-cellcentric-with-epigenetics-approach-to-cancer/
我们的一个重要里程碑口服抗癌药物,inobrodib。从@pfizer 25美元的战略投资。见新闻稿:https://www.cellcentric.com/press-release/cellcentric-announces-25m-strategic-investment-from-pfizer/
我们的首席医疗官评论FDA孤儿药指定消息。有助于加快开发/采用治疗多发性骨髓瘤。参见:https://www.cellcentric.com/press-release/cellcentric-granted-fda-orphan-drug-designation-for-inobrodib-ccs1477-for-the-treatment-of-multiple-myeloma/
我们开创性的重要一步p300 / CBP抑制剂,inobrodib。影响癌症患者。我们感谢@endpts覆盖许多新闻:https://endpts.com/exclusive-pfizer-to-invest-25m-into-uk-biotech-cellcentric-with-epigenetics-approach-to-cancer/
我们的一个重要里程碑口服抗癌药物,inobrodib。从@pfizer 25美元的战略投资。见新闻稿:https://www.cellcentric.com/press-release/cellcentric-announces-25m-strategic-investment-from-pfizer/
我们的首席医疗官评论FDA孤儿药指定消息。有助于加快开发/采用治疗多发性骨髓瘤。参见:https://www.cellcentric.com/press-release/cellcentric-granted-fda-orphan-drug-designation-for-inobrodib-ccs1477-for-the-treatment-of-multiple-myeloma/